Blood sample
Pre-clinicalCompleted 0 watching 0 views this week๐ค Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Thalassemia
Conditions
Thalassemia, Sickle Cell Disease, Myelodysplasia
Trial Timeline
Mar 1, 2012 โ Mar 1, 2015
NCT ID
NCT01911871About Blood sample
Blood sample is a pre-clinical stage product being developed by Novartis for Thalassemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01911871. Target conditions include Thalassemia, Sickle Cell Disease, Myelodysplasia.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01911871 | Pre-clinical | Completed |
Competing Products
20 competing products in Thalassemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Luspatercept | Merck | Phase 2 | 52 |
| luspatercept | Merck | Phase 2 | 52 |
| ACE-536 | Merck | Phase 2 | 52 |
| luspatercept | Merck | Phase 2 | 52 |
| Deferasirox | Novartis | Approved | 85 |
| deferasirox + placebo | Novartis | Phase 2 | 52 |
| Zoledronic acid + Placebo | Novartis | Phase 2/3 | 65 |
| deferasirox | Novartis | Approved | 85 |
| deferasirox | Novartis | Phase 3 | 77 |
| ICL670 + deferoxamine | Novartis | Phase 3 | 77 |
| ruxolitinib | Novartis | Phase 2 | 52 |
| Deferasirox | Novartis | Phase 2 | 52 |
| Deferasirox dispersable tablet (DT) + Deferasirox film coated tablet (FCT) | Novartis | Phase 2 | 52 |
| Zoledronic Acid | Novartis | Approved | 85 |
| Deferasirox | Novartis | Phase 2 | 52 |
| Deferasirox | Novartis | Approved | 85 |
| Deferasirox + Deferoxamine (DFO) | Novartis | Phase 2 | 52 |
| Deferasirox | Novartis | Phase 1 | 33 |
| Deferasirox | Novartis | Phase 3 | 77 |
| Deferasirox | Novartis | Phase 2 | 52 |